Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Blood

Volumn 128, Issue 9, 2016, Pages 1246-1249

  Mossner, Maximilian ^a   Jann, Johann Christoph ^a   Wittig, Janina ^a   Nolte, Florian ^a   Fey, Stephanie ^a   Nowak, Verena ^a   Obländer, Julia ^a   Pressler, Jovita ^a   Palme, Iris ^a   Xanthopoulos, Christina ^a   Boch, Tobias ^a   Metzgeroth, Georgia ^a   Röhl, Henning ^a   Witt, Stephanie H ^a   Dukal, Helene ^a   Klein, Corinna ^b   Schmitt, Steffen ^b   Gelß, Patrick ^c   Platzbecker, Uwe ^d   Balaian, Ekaterina ^d   Fabarius, Alice ^a   Blum, Helmut ^e   Schulze, Torsten J ^a   Meggendorfer, Manja ^f   Haferlach, Claudia ^f   Trumpp, Andreas ^b,g   Hofmann, Wolf Karsten ^a   Medyouf, Hind ^a,b,h   Nowak, Daniel ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^g Exp Hematology Group Heidelberg Institute for Stem Cell Technology and Experimental Medicine GGmbH   (Germany)

^h INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; LENALIDOMIDE; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; GENETIC HETEROGENEITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MODIFIER GENE; MOLECULAR CLONING; MOLECULAR EVOLUTION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; RNA SPLICING; SOMATIC MUTATION; TREATMENT RESPONSE; ANIMAL; CANCER TRANSPLANTATION; GENETICS; HEMATOPOIESIS; KNOCKOUT MOUSE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MOUSE; MUTATION; MYELODYSPLASTIC SYNDROMES; NONOBESE DIABETIC MOUSE; XENOGRAFT;

ANIMALS; FEMALE; HEMATOPOIESIS; HETEROGRAFTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM TRANSPLANTATION;

EID: 84987657386     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-679167     Document Type: Article

References (52)

1. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
2. Gelsi-Boyer V, Trouplin V, Adéläide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800.
3. Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013; 45(10):1232-1237.
4. Papaemmanuil E, Cazzola M, Boultwood J, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15): 1384-1395.
5. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
6. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241-247.
7. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627, quiz 3699.
8. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9): 1367-1376.
9. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.
10. Busque L, Paquette Y, Provost S, et al. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood. 2009;113(15):3472-3474.
11. Mossner M, Nolte F, Hütter G, et al. Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay. J Med Genet. 2013;50(2):108-117.
12. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
13. Jaiswal S, Fontanillas P, Flannick J, et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498.
14. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12): 1472-1478.
15. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.
16. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44(6):651-658.
17. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44(6): 642-650.
18. Jann JC, Nowak D, Nolte F, et al. Application of a short tandem repeat based PCR assay for chronological monitoring of myelodysplastic syndrome (MDS) patients with deletion of chromosome 5q following lenalidomide treatment [abstract]. Blood. 2015;126(23). Abstract 2891.
19. Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14(6):824-837.
20. Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood. 2010;115(18):3704-3707.
21. Miller CA, White BS, Dees ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLOS Comput Biol. 2014;10(8):e1003665.
22. Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45(10): 1141-1149.
23. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111(7):2548-2553.
24. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149):149ra118.
25. Pløen GG, Nederby L, Guldberg P, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol. 2014;167(4):478-486.
26. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan- Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506(7488):328-333.
27. published correction appears in Nature. 2014;508(7496):420
28. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
29. Mayle A, Yang L, Rodriguez B, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015;125(4): 629-638.
30. Abdel-Waab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013; 210(12):2641-2659.
31. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell selfrenewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24.
32. Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015; 27(5):617-630.
33. Woll PS, Kjällquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794-808.
34. [published correction appears in Cancer Cell. 2015;27(4):603-605
35. 2014;25(6):861]
36. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
37. Shlush LI, Minden MD. Preleukemia: the normal side of cancer. Curr Opin Hematol. 2015;22(2): 77-84.
38. Kats LM, Reschke M, Taulli R, et al. Protooncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014; 14(3):329-341.
39. DiNardo C, de Botton S, Pollyea DA, et al. Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study [abstract]. Blood. 2015;126(23). Abstract 1306.
40. Nilsson L, Astrand-Grundström I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96(6):2012-2021.
41. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals lowabundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116(19):3923-3932.
42. Chesnais V, Renneville A, Toma A, et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2016;127(6):749-760.
43. Walter MJ, Shen D, Shao J, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27(6):1275-1282.
44. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-3545.
45. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090-1098.
46. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330): 356-361.
47. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382):506-510.
48. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-1066.
49. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892.
50. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
51. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemiainitiating cells. Nature. 2011;469(7330):362-367.
52. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121(12):2186-2198.